Compare Marriott International Inc (MAR) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Novartis AG — how do they compare? Marriott International Inc trades at $366.39 (market cap $96.76B), while Novartis AG trades at $154.54 (market cap $290.25B). The key difference: Novartis AG is far larger — about 3× Marriott International Inc 's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| MAR | NVS | |
|---|---|---|
Market Cap | $96.76B | $290.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $168.62 |
52-Week Low | $255.35 | $113.50 |
Enterprise Value | $113.71B | $330.27B |
Dividend Yield | 0.8% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $366.83, up 0.16% on the day, with technical indicators showing a bearish trend near key support at $364. The company reported Q1 2026 EPS of $2.72, beating expectations, and maintains a net income margin of 9.72% amid steady revenue growth. Recent developments include a strategic partnership with Coca-Cola and the launch of an AI-powered travel search tool, Ask Bonvoy, enhancing its digital offerings.
The outlook is mixed: analyst consensus targets $387.92 with 44% buy ratings, but rising debt-to-asset ratios and hotel owner disputes over the Bonvoy program pose risks. Earnings on August 3, 2026, will be critical for confirming growth trajectory amid competitive travel sector pressures.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
